Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NivoMela: Adjuvant Nivolumab in Stage II High-risk Melanoma
NCT04309409Phase 3Active, not recruiting
- Sponsor
- Universitätsmedizin Essen
- Start
- Jul 2020
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in cutaneous melanoma (CM), sponsored by Universitätsmedizin Essen. Started Jul 2020; status: active, not recruiting.
02
Drugs
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT04309409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04309409.